Imaging tumor metabolism using positron emission tomography

Cancer Journal (United States)

Volumn 21, Issue 2, 2015, Pages 129-136

  Lewis, David Y ^a   Soloviev, Dmitry ^a   Brindle, Kevin M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

metabolic tracers; PET radiotracers; PET MRI; Positron emission tomography (PET); tumor metabolism

Indexed keywords

AMINO ACID DERIVATIVE; AMINO ACID TRANSPORTER; CARBOHYDRATE; FATTY ACID DERIVATIVE; FLUORODEOXYGLUCOSE F 18; AMINO ACID; FATTY ACID; RADIOPHARMACEUTICAL AGENT;

AMINO ACID METABOLISM; CARBOHYDRATE METABOLISM; FATTY ACID METABOLISM; HUMAN; NEOPLASM; PENTOSE PHOSPHATE CYCLE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; ANIMAL; DIAGNOSTIC IMAGING; ENERGY METABOLISM; METABOLISM; NEOPLASMS; PROCEDURES;

AMINO ACIDS; ANIMALS; CARBOHYDRATE METABOLISM; DIAGNOSTIC IMAGING; ENERGY METABOLISM; FATTY ACIDS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84926633413     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000105     Document Type: Review

References (128)

1. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683-693.
2. Brindle K. New approaches for imaging tumour responses to treatment. Nat Rev Cancer. 2008;8:94-107.
3. Huang C,McConathy J. Radiolabeled amino acids for oncologic imaging. J NuclMed. 2013;54:1007-1010.
4. Pruim J, Willemsen AT, Molenaar WM, et al. Brain tumors: L-[1-C-11]tyrosine PET for visualization and quantification of protein synthesis rate. Radiology. 1995;197:221-226.
5. Lewis DY, Boren J, Shaw GL, et al. Late imaging with [1-11C]acetate improves detection of tumor fatty acid synthesis with PET. J Nucl Med. 2014;55:1144-1149.
6. Vavere AL, Kridel SJ, Wheeler FB, et al. 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med. 2008;49:327-334.
7. Soloviev D, Lewis D, Honess D, et al. [18F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur J Cancer. 2012;48:416-424.
8. Tomasi G, Aboagye EO. Introduction to the analysis of PET data in oncology. J Pharmacokinet Pharmacodyn. 2013;40:419-436.
9. Tomasi G, Turkheimer F, Aboagye E. Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future. Mol Imaging Biol. 2012;14:131-146.
10. Schwaiger M, Wester HJ. How many PET tracers do we need? J Nucl Med. 2011;52:36S-41S.
11. Gallagher FA, Bohndiek SE, Kettunen MI, et al. Hyperpolarized 13C MRI and PET: in vivo tumor biochemistry. J Nucl Med. 2011;52: 1333-1336.
12. Waterton JC, Pylkkanen L. Qualification of imaging biomarkers for oncology drug development. Eur J Cancer. 2012;48:409-415.
13. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. 2004-2013. Bethesda, MD: National Center for Biotechnology Information. Available at: http://www.ncbi.nlm.nih.gov/books/NBK5330/. Accessed February 17, 2015.
14. Di Chiro G, DeLa Paz RL, Brooks RA, et al. Glucose utilization of cerebral gliomasmeasured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology. 1982;32:1323-1329.
15. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27: 441-464.
16. Pedersen P. Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg effect", i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr. 2007;39:211-222.
17. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A. 2007;104:19345-19350.
18. Rodrigues TB, Serrao EM, Kennedy BW, et al.Magnetic resonance imaging of tumor glycolysis using hyperpolarized 13C-labeled glucose. Nat Med. 2014;20:93-97.
19. Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F-FDG PET in oncology. J NuclMed. 2008;49:480-508.
20. Furumoto S, Shinbo R, Iwata R, et al. In vitro and in vivo characterization of 2-deoxy-2-18F-fluoro-D-mannose as a tumor-imaging agent for PET. J NuclMed. 2013;54:1354-1361.
21. Arumugam T, Paolillo V, Young D, et al. Preliminary evaluation of 1-[18F]fluoroethyl-b-D-lactose ([18F]FEL) for detection of pancreatic cancer in nude mouse orthotopic xenografts. Nucl Med Biol. 2014;41:833-840.
22. Wuest M, Trayner BJ, Grant TN, et al. Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer. Nucl Med Biol. 2011;38:461-475.
23. Sorensen M, Frisch K, Bender D, et al. The potential use of 2-[18F] fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2011;38: 1723-1731.
24. Fukushima N, Koopmann J, Sato N, et al. Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma. Mod Pathol. 2005;18:779-787.
25. Demaugre F, Philippe Y, Sar S, et al. HIP/PAP, a C-type lectin overexpressed in hepatocellular carcinoma, binds the RII alpha regulatory subunit of cAMP-dependent protein kinase and alters the cAMP-dependent protein kinase signalling. Eur J Biochem. 2004;271:3812-3820.
26. Witney TH, Kettunen MI, Day SE, et al. A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized 13C-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia. 2009;11:574-582.
27. Gowrishankar G, Zitzmann-Kolbe S, Junutula A, et al. GLUT 5 is not over-expressed in breast cancer cells and patient breast cancer tissues. PLoS One. 2011;6:e26902.
28. Smith TA. The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation. Nucl Med Biol. 2001;28:1-4.
29. Carroll L, Witney TH, Aboagye EO. Design and synthesis of novel 18F-radiolabelled glucosamine derivatives for cancer imaging. Med Chem Comm. 2013;4:653-656.
30. Witney TH, Carroll L, AlamIS, et al. A novel radiotracer to image glycogen metabolism in tumors by positron emission tomography. Cancer Res. 2014; 74:1319-1328.
31. Lai K, KlapaMI. Alternative pathways of galactose assimilation: could inverse metabolic engineering provide an alternative to galactosemic patients? Metab Eng. 2004;6:239-244.
32. Stincone A, Prigione A, Cramer T, et al. The return of metabolism: biochemistry and physiology of the pentose phosphate pathway [published online ahead of print September 22, 2014]. Biol Rev. doi: 10.1111/brv.12140.
33. Clark PM, FloresG, EvdokimovNM, et al. Positron emission tomography probe demonstrates a striking concentration of ribose salvage in the liver. Proc Natl Acad Sci U S A. 2014;111:E2866-E2874.
34. Fischman AJ,YuYM, Livni E, et al.Muscle protein synthesis by positronemission tomography with l-[methyl-11C]methionine in adult humans. Proc Natl Acad Sci U S A. 1998;95:12793-12798.
35. Hawkins RA, Huang SC, Barrio JR, et al. Estimation of local cerebral protein synthesis rates with L-[l-11C]leucine and PET: methods, model, and resultsin animals and humans. J Cereb Blood Flow Metab. 1989;9: 446-460.
36. Plaat B, Kole A, Mastik M, et al. Protein synthesis rate measured with l-[1-11C]tyrosine positron emission tomography correlates with mitotic activity and MIB-1 antibody-detected proliferation in human soft tissue sarcomas. Eur J Nucl Med. 1999;26:328-332.
37. van den Bergh AC, Pruim J, Links TP, et al. Tyrosine positron emission tomography and protein synthesis rate in pituitary adenoma: different effects of surgery and radiation therapy. Radiother Oncol. 2011;98:213-216.
38. Bustany P, Chatel M, Derlon JM, et al. Brain tumor protein synthesis and histological grades: A study by positron emission tomography (PET) with C11-L-methionine. J Neurooncol. 1986;3:397-404.
39. WeberWA,Wester HJ, Grosu AL, et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med. 2000;27:542-549.
40. Becherer A, Karanikas G, Szabo M, et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging. 2003;30:1561-1567.
41. Nawashiro H, Otani N, Shinomiya N, et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer. 2006;119:484-492.
42. Betsunoh H, Fukuda T, Anzai N, et al. Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma. BMC Cancer. 2013;13:509.
43. Kaira K, Sunose Y, Arakawa K, et al. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer. 2012;107:632-638.
44. Takeuchi K, Ogata S, Nakanishi K, et al. LAT1 expression in non-smallcell lung carcinomas: analyses by semiquantitative reverse transcription-PCR (237 cases) and immunohistochemistry (295 cases). Lung Cancer. 2010;68:58-65.
45. Floeth FW, SabelM, Stoffels G, et al. Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions. J NuclMed. 2008;49:730-737.
46. Piroth MD, Pinkawa M, Holy R, et al. Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011; 80:176-184.
47. Weckesser M, Langen KJ, Rickert CH, et al. O-(2-[18F]fluorethyl)-Ltyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging. 2005;32:422-429.
48. Kaira K, Sunose Y, Arakawa K, et al. Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma. Histopathology. 2015;66:234-243.
49. Shimizu K, Kaira K, Tomizawa Y, et al. ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer. Br J Cancer. 2014;110:2030-2039.
50. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol. 2005;15:254-266.
51. Nanni C, Schiavina R, Brunocilla E, et al. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. Clin Genitourin Cancer. 2014;12:106-110.
52. Turkbey B, Mena E, Shih J, et al. Localized prostate cancer detection with 18F-FACBC PET/CT: comparison with MR imaging and histopathologic analysis. Radiology. 2014;270:849-856.
53. YuW, McConathy J,Williams L, et al. Synthesis, radiolabeling, and biological evaluation of (R)-and (S)-2-amino-3-[18F]fluoro-2-methylpropanoic acid (FAMP) and (R)-and (S)-3-[18F]fluoro-2-methyl-2-N-(methylamino) propanoic acid (NMeFAMP) as potential PET radioligands for imaging brain tumors. J Med Chem. 2010;53:876-886.
54. Yu W, McConathy J, Olson JJ, et al. System a amino acid transport-targeted brain and systemic tumor PET imaging agents 2-amino-3-[(18)F]fluoro-2-methylpropanoic acid and 3-[(18)F]fluoro-2-methyl-2-(methylamino) propanoic acid. Nucl Med Biol. 2015;42:8-18.
55. Webster JM,Morton CA, Johnson BF, et al. Functional imaging of oxidative stress with a novel PET imaging agent, 18F-5-fluoro-L-aminosuberic acid. J NuclMed. 2014;55:657-664.
56. Krasikova RN, Kuznetsova OF, Fedorova OS, et al. 4-[18F]Fluoroglutamic acid (BAY 85-8050), a new amino acid radiotracer for PET imaging of tumors: synthesis and in vitro characterization. J Med Chem. 2011; 54:406-410.
57. Ploessl K, Wang L, Lieberman BP, et al. Comparative evaluation of 18F-labeled glutamic acid and glutamine as tumor metabolic imaging agents. J NuclMed. 2012;53:1616-1624.
58. Koglin N, Mueller A, Berndt M, et al. Specific PET imaging of xC-transporter activity using a 18F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism. Clin Cancer Res. 2011; 17:6000-6011.
59. Baek S, Mueller A, Lim YS, et al. (4S)-4-(3-18F-fluoropropyl)-Lglutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies. J Nucl Med. 2013;54:117-123.
60. Baek S, Choi CM, Ahn SH, et al. Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC-transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin Cancer Res. 2012;18:5427-5437.
61. Lu SC. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J. 1999;13:1169-1183.
62. Lewerenz J, Hewett SJ, Huang Y, et al. The cystine/glutamate antiporter system xc-in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal. 2013;18:522-555.
63. Ishimoto T, Nagano O, Yae T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc-and thereby promotes tumor growth. Cancer Cell. 2011;19:387-400.
64. Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008;105:18782-18787.
65. QuW, Oya S, Lieberman BP, et al. Preparation and characterization of L-[5-11C]-glutamine for metabolic imaging of tumors. J Nucl Med. 2012;53: 98-105.
66. Wu F, OrleforsH, Bergstrom M, et al. Uptake of 14C-and 11C-labeled glutamate, glutamine and aspartate in vitro and in vivo. Anticancer Res. 2000; 20:251-256.
67. Lieberman BP, Ploessl K, Wang L, et al. PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. J Nucl Med. 2011;52: 1947-1955.
68. Venneti S, Dunphy MP, Zhang H, et al. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Sci Transl Med. 2015;7:274ra17.
69. Wu Z, Zha Z, Li G, et al. [18F](2S,4S)-4-(3-fluoropropyl)glutamine as a tumor imaging agent. Mol Pharm. 2014;11:3852-3866.
70. Bozza PT, Viola JPB. Lipid droplets in inflammation and cancer. Prostaglandins Leukotr Essent Fatty Acids. 2010;82:243-250.
71. Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer. 2013;13:227-232.
72. DeBerardinis RJ, Sayed N, Ditsworth D, et al. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev. 2008;18:54-61.
73. Iozzo P, Bucci M, Roivainen A, et al. Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals. Gastroenterology. 2010;139:846-856.
74. Pandey MK, Bansal A, DeGrado TR. Fluorine-18 labeled thia fatty acids for PET imaging of fatty acid oxidation in heart and cancer. Heart Metab. 2011;51:15-19.
75. DeGrado TR, Bhattacharyya F, Pandey MK, et al. Synthesis and preliminary evaluation of 18-18F-fluoro-4-thia-oleate as a PET probe of fatty acid oxidation. J NuclMed. 2010;51:1310-1317.
76. Daniëls VW, Smans K, Royaux I, et al. Cancer cells differentially activate and thrive on de novo lipid synthesis pathways in a low-lipid environment. PLoS One. 2014;9:e106913.
77. Mashimo T, Pichumani K, Vemireddy V, et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 2014;159: 1603-1614.
78. Lyssiotis CA, Cantley LC. Acetate fuels the cancer engine. Cell. 2014; 159:1492-1494.
79. Yoshii Y,Waki A, Furukawa T, et al. Tumor uptake of radiolabeled acetate reflects the expression of cytosolic acetyl-CoA synthetase: implications for the mechanism of acetate PET. Nucl Med Biol. 2009;36:771-777.
80. Nishii R, Tong W, Wendt R, et al. Pharmacokinetics, metabolism, biodistribution, radiation dosimetry, and toxicology of 18F-fluoroacetate (18F-FACE) in non-human primates. Mol Imaging Biol. 2012;14: 213-224.
81. Lindhe O, Sun A, Ulin J, et al. [18F]Fluoroacetate is not a functional analogue of [11C]acetate in normal physiology. Eur J Nucl MedMol Imaging. 2009;36:1453-1459.
82. Pillarsetty N, Punzalan B, Larson SM. 2-18F-fluoropropionic acid as a PET imaging agent for prostate cancer. J NuclMed. 2009;50:1709-1714.
83. Pisaneschi F, Witney TH, Iddon L, et al. Synthesis of [18F]fluoro-pivalic acid: an improved PET imaging probe for the fatty acid synthesis pathway in tumours. Med Chem Comm. 2013;4:1350-1353.
84. Witney TH, Pisaneschi F, Alam IS, et al. Preclinical evaluation of 3-18Ffluoro-2,2-dimethylpropionic acid as an imaging agent for tumor detection. J Nucl Med. 2014;55:1506-1512.
85. DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001;61:110-117.
86. Umbehr MH, Muntener M, Hany T, et al. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013; 64:106-117.
87. de Vogel S, Tan AC, Weekes CD, et al. Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer-a large nested case-control study within the JANUS cohort in Norway. Int J Cancer. 2014;134:197-206.
88. Gibellini F, Smith TK. The Kennedy pathway-de novo synthesis of phosphatidylethanolamine and phosphatidylcholine. IUBMB Life. 2010; 62:414-428.
89. Witney TH, Alam IS, Turton DR, et al. Evaluation of deuterated 18F-and 11C-labeled choline analogs for cancer detection by positron emission tomography. Clin Cancer Res. 2012;18:1063-1072.
90. Smith G, Zhao Y, Leyton J, et al. Radiosynthesis and pre-clinical evaluation of [18F]fluoro-[1,2-2H4]choline. Nucl Med Biol. 2011;38:39-51.
91. Challapalli A, Sharma R, Hallett WA, et al. Biodistribution and radiation dosimetry of deuterium-substituted 18F-fluoromethyl-[1, 2-2H4]choline in healthy volunteers. J NuclMed. 2014;55:256-263.
92. Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer. 2013;13:572-583.
93. Jain M, Nilsson R, Sharma S, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science. 2012;336: 1040-1044.
94. Nakajima EC, van Houten B. Metabolic symbiosis in cancer: refocusing the Warburg lens. Mol Carcinog. 2013;52:329-337.
95. Tedeschi PM, Markert EK, Gounder M, et al. Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell Death Dis. 2013;4:e877.
96. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2012;2:881-898.
97. Brooks GA. Cell-cell and intracellular lactate shuttles. J Physiol. 2009; 587:5591-5600.
98. Rajagopalan KN, DeBerardinis RJ. Role of glutamine in cancer: therapeutic and imaging implications. J Nucl Med. 2011;52:1005-1008.
99. Phang JM. The proline regulatory axis and cancer. Front Oncol. 2012;2:60.
100. Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab. 2001;21:635-652.
101. Tomasi G, Kimberley S, Rosso L, et al. Double-input compartmental modeling and spectral analysis for the quantification of positron emission tomography data in oncology. Phys Med Biol. 2012;57:1889-1906.
102. Mori Y, Manabe O, Naya M, et al. Improved spillover correction model to quantify myocardial blood flow by 11C-acetate PET: comparison with 15O-H2O PET. Ann Nucl Med. 2015;29:15-20.
103. van den Hoff J, Burchert W, Wolpers HG, et al. A kinetic model for cardiac PETwith [1-carbon-11]-acetate. J NuclMed. 1996;37:521-529.
104. Schiepers C, Hoh CK, Nuyts C, et al. 1-11C-acetate kinetics of prostate cancer. J NuclMed. 2008;49:206-215.
105. Brindle KM, Bohndiek SE, Gallagher FA, et al. Tumor imaging using hyperpolarized 13C magnetic resonance spectroscopy. Magn Reson Med. 2011;66:505-519.
106. Comment A, Merritt ME. Hyperpolarized magnetic resonance as a sensitive detector of metabolic function. Biochemistry. 2014;53: 7333-7357.
107. Nelson SJ, Kurhanewicz J, Vigneron DB, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized 1-C-13 pyruvate. Sci Transl Med. 2013;5: 10.
108. Judenhofer MS, Wehrl HF, Newport DF, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med. 2008; 14:459-465.
109. Poulin E, Lebel R, Croteau E, et al. Conversion of arterial input functions for dual pharmacokinetic modeling using Gd-DTPA/MRI and 18F-FDG/PET. Magn Reson Med. 2013;69:781-792.
110. Frese KK, TuvesonDA. Maximizing mouse cancer models. Nat Rev Cancer. 2007;7:645-658.
111. Cho H, Herzka T, Zheng W, et al. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov. 2014;4:318-333.
112. Rodriguez E, Mannion L, D'Santos P, et al. Versatile and enhanced tumour modelling in mice via somatic cell transduction. J Pathol. 2014; 232:449-457.
113. Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9: 338-350.
114. Huijbers IJ, Bin Ali R, Pritchard C, et al. Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. EMBO Mol Med. 2014;6:212-225.
115. Boj SF, Hwang CI, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160:324-338.
116. Politi K, PaoW. How genetically engineeredmouse tumor models provide insights into human cancers. J ClinOncol. 2011;29:2273-2281.
117. Pedersen PL. Voltage dependent anion channels (VDACs): a brief introduction with a focus on the outer mitochondrial compartment's roles together with hexokinase-2 in the "Warburg effect" in cancer. J Bioenerg Biomembr. 2008;40:123-126.
118. Carroll L, Perumal M, Vasdev N, et al. Radiosynthesis and in vivo tumor uptake of 2-deoxy-2-[18F] fluoro-myo-inositol. Bioorg Med Chem Lett. 2012;22:6148-6150.
119. Dunet V, Rossier C, Buck A, et al. Performance of 18F-fluoro-ethyltyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic reviewandmetaanalysis.JNuclMed. 2012;53:207-214.
120. Lapa C, Linsenmann T, Monoranu CM, et al. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients. J Nucl Med. 2014;55:1611-1616.
121. Wiriyasermkul P, Nagamori S, Tominaga H, et al. Transport of 3-fluoro-L-alpha-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. J Nucl Med. 2012;53: 1253-1261.
122. Prenant C, Theobald A, Siegel T, et al. Carbon-11 labelled analogs of alanine by the strecker synthesis. J Label Compd Radiopharm. 1995; 36:579-586.
123. Kit S, Greenberg DM. Tracer studies on the metabolism of the Gardner lymphosarcoma. III. The rate of radioactive alanine and glycine uptake into the protein of lymphosarcoma cells and normal spleen cells. Cancer Res. 1951;11:500-504.
124. Wang L, Zha Z, Qu W, et al. Synthesis and evaluation of 18F labeled alanine derivatives as potential tumor imaging agents. Nucl Med Biol. 2012;39:933-943.
125. Muller A, Chiotellis A, Keller C, et al. Imaging tumour ATB0,+ transport activity by PET with the cationic amino acid O-2((2-[18F]fluoroethyl) methyl-amino)ethyltyrosine. Mol Imaging Biol. 2014;16:412-420.
126. Mitsuoka K, Miyoshi S, Kato Y, et al. Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+/peptide transporter. J Nucl Med. 2008;49:615-622.
127. Turkman N, Gelovani JG, Alauddin MM. Radiosynthesis of N5-[18F] fluoroacetylornithine (N5-[18F]FAO) for PET imaging of ornithine decarboxylase (ODC) inmalignant tumors. J Label Compd Radiopharm. 2011; 54:33-37.
128. Angsten G, Valind S, Takalo R, et al. Inhibition of carnitine-acyl transferase I by oxfenicine studied in vivo with [11C]-labeled fatty acids. Nucl Med Biol. 2005;32:495-503.